EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Integrated Molecular Risk Stratification and Measurable Residual Disease‐Guided Consolidation Improve Outcomes in Pediatric Non‐Down Syndrome Acute Megakaryoblastic Leukemia

Chunxia Cai, Yiqiao Chen, Chunping Wu, Xiaoqin Feng iD, Chunfu Li, Mincui Zheng, Huirong Mai iD, Lihua Yang, Hua Jiang, Xiangling He, Hong Wen, Honggui Xu und 4 weitere

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71879 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 17.05.2026. Verfasst von Chunxia Cai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Provincial Key Laboratory on Hematology, Department of Paeditric Hematology, Fujian Institute of Hematology, Fujian Medical University Union H…. Hauptthemen laut MEDLINE: Leukemia, Megakaryoblastic, Acute, Antineoplastic Combined Chemotherapy Protocols, Consolidation Chemotherapy. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Clinical Specialty Discipline Construction Program, Fujian Provincial Clinical Research Center for Hematological Malignancies, National Key Clinical Specialty Discipline Construction Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of pediatric acute megakaryoblastic leukemia (AMKL) without Down syndrome (non‐DS‐AMKL) remains challenging due to suboptimal induction responses and poor survival. This study assessed the efficacy of fludarabine, cytarabine, granulocyte colony‐stimulating factor, and idarubicin (FLAG‐IDA) in non‐DS‐AMKL and evaluated the role of risk‐adapted consolidation strategies, including hematopoietic stem cell transplantation (HSCT) during first complete remission (CR1), guided by genetic profiles and measurable residual disease (MRD) dynamics. In this multicenter retrospective study from China, we analyzed 58 non‐DS‐AMKL patients treated with FLAG‐IDA ( n = 50) or daunorubicin, cytarabine, etoposide (DAE) ( n = 8) induction, followed by risk‐adapted consolidation. FLAG‐IDA demonstrated CR rates comparable to those with DAE (first‐course: 70.0% vs. 87.5%, p = 0.423; cumulative: 82.0% vs. 87.5%, p = 1.000). Compared with other AML subtypes, non‐DS‐AMKL showed inferior 5‐year overall survival (OS) (61.7% vs. 78.2%, p = 0.001) and event‐free survival (EFS) (58.5% vs. 68.8%, p = 0.045), attributable to a higher relapse rate (34.8% vs. 19.5%, p = 0.002). High‐risk genetics predicted worse outcomes. HSCT in CR1 significantly improved survival for high‐risk or poor responders. CR with MRD negativity after second induction predicted superior OS and EFS ( p < 0.001). Risk‐adapted HSCT and MRD‐guided stratification are critical for non‐DS‐AMKL management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Megakaryoblastic, AcuteAntineoplastic Combined Chemotherapy ProtocolsConsolidation ChemotherapyHumansNeoplasm, ResidualFemaleRetrospective StudiesChildMaleChild, PreschoolCytarabineVidarabineRisk AssessmentIdarubicinHematopoietic Stem Cell TransplantationInfantAdolescentGranulocyte Colony-Stimulating FactorDaunorubicinRemission InductionEtoposideTreatment Outcome

Stichwörter der Autor:innen

acute myeloid leukemiachemotherapyclinical observationscytogenetics

Substanzen

CytarabineVidarabineIdarubicinfludarabineGranulocyte Colony-Stimulating FactorDaunorubicinEtoposide

Autor:innen und Institutionen

  • Fujian Provincial Key Laboratory on Hematology, Department of Paeditric Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Nanfang-Chunfu Children's Institute of Hematology & Oncology, Taixin Hospital, Dongguan, China.
  • Department of Pediatric Hematology/Oncology, Hunan Children's Hospital, Changsha, China.
  • Department of Pediatric Hematology/Oncology, Shenzhen Children's Hospital, Shenzhen, China.
  • Department of Pediatrics, Zhujiang Hospital of Southern Medical University, Guangzhou, China.

ORCID-Profile: Xiaoqin Feng, Huirong Mai, Chun Chen, Yongzhi Zheng

Förderung

  • National Key Clinical Specialty Discipline Construction Program
  • Fujian Provincial Clinical Research Center for Hematological Malignancies
  • National Key Clinical Specialty Discipline Construction Program of China

Zitieren

APA

Cai, C., Chen, Y., Wu, C., Feng, X., Li, C., Zheng, M., Mai, H., Yang, L., Jiang, H., He, X., Wen, H., Xu, H., Chen, C., Le, S., Li, N., & Zheng, Y. (2026). Integrated Molecular Risk Stratification and Measurable Residual Disease‐Guided Consolidation Improve Outcomes in Pediatric Non‐Down Syndrome Acute Megakaryoblastic Leukemia. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71879

Vancouver

Cai C, Chen Y, Wu C, Feng X, Li C, Zheng M, et al. Integrated Molecular Risk Stratification and Measurable Residual Disease‐Guided Consolidation Improve Outcomes in Pediatric Non‐Down Syndrome Acute Megakaryoblastic Leukemia. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71879

BibTeX
@article{Cai2026,
  author = {Cai, Chunxia and Chen, Yiqiao and Wu, Chunping and Feng, Xiaoqin and Li, Chunfu and Zheng, Mincui and Mai, Huirong and Yang, Lihua and Jiang, Hua and He, Xiangling and Wen, Hong and Xu, Honggui and Chen, Chun and Le, Shaohua and Li, Nainong and Zheng, Yongzhi},
  title = {Integrated Molecular Risk Stratification and Measurable Residual Disease‐Guided Consolidation Improve Outcomes in Pediatric Non‐Down Syndrome Acute Megakaryoblastic Leukemia},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71879}
}
Kostenlos starten →